Latest News in the pharma Industry
Research & Development
Shire submits IND application to FDA for gene therapy candidate SHP654 for treatment of hemophilia A
9 Jul 2017
SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A.
Read more
Almac Discovery granted Orphan Drug Designation for ALM201 programme in ovarian cancer
7 Jul 2017
ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL.
Read more
Phase III study evaluating safety and efficacy of adjuvant Opdivo in resected melanoma patients meets primary endpoint
6 Jul 2017
Opdivo demonstrates superior recurrence-free survival versus Yervoy in adjuvant setting in CheckMate -238.
Read more
First patients treated in Phase I/II trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer
4 Jul 2017
NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumours
Read more
Common antimicrobials help patients recover from MRSA abscesses
3 Jul 2017
NIAID-funded trial counters current thinking about treatment effectiveness.
Read more
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC
29 Jun 2017
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival compared with SOC chemotherapy with maintenance.
Read more
Researchers develop microneedle patch for flu vaccination
28 Jun 2017
The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.
Read more
Merck's anacetrapib meets primary endpoint
28 Jun 2017
Company to consider whether to file new drug applications with the FDA and other regulatory agencies.
Read more
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS
25 Jun 2017
Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.
Read more
Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer
25 Jun 2017
New indication supported by results of Phase III PALOMA-3 Trial of Ibrance in combination with fulvestrant.
Read more
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP
23 Jun 2017
If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe.
Read more
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance
21 Jun 2017
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.
Read more